Company
NASDAQ:BIIB
Biogen Inc is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich’s ataxia.
60 stories · page 2 of 3
The company is holding a doctor-patient education conference on March 30 in San Juan to talk to patients and their families about how Hyalolex is a 'gentler treatment journey' for Alzheimer’s patients
Investments and investor services
Also making moves were Apple, Biogen, Vale and Tesla
Investments and investor services
Also making moves were Nike, Darden Restaurants, Micron and Conagra
Kraft Heinz shares picked up traction after a Morgan Stanley upgrade
The success of Spinraza helped to offset decreased demand for its multiple sclerosis treatment Tecfidera
Experts are optimistic biotechs may be turning the corner on the mind-robbing disease after years of failure
On a day where tech stocks are seen falling following Facebook results; Qualcomm Inc was another stock bucking the trend, with shares up
The Nasdaq-listed firm said its earnings for the quarter rose to US$867mln, or US$4.18 per share, up from US$863mln, or US$4.07 per share in the year-earlier period
Investments and investor services
The tech company warned investors earlier this week that it was cash-strapped and may soon file for bankruptcy
Also in the frame before the bell was Aegean Marine Petroleum Network Inc and Wells Fargo & Co
Japanese company TMS' drug TMS-007 is designed to break down blood clots and prevent inflammation
PF-04958242 helps the central nervous system to send and receive ‘messages’, and Biogen is looking to take it through Phase IIb trials later this year
Investments and investor services
Britain's blue-chip benchmark closed down over nine points, or 0.13% to 7,214..
Biogen and AbbVie have halted sales of the multiple sclerosis treatment following several reports of brain inflammation in people who took the drug
Biogen’s recently-launched spinal muscular atrophy treatment, Spinraza, helped to push revenues in the final three months of 2017 up by 15% to a record US$3.31bn
Bioverativ shares jumped in pre-market trade, but Sanofi was the worst performer on France’s CAC 40, with analysts calling the deal expensive
The speculation comes after Acorda on Thursday provided preliminary guidance for its 2017 sales to be US$542mln, an increase of approximately 10% from 2016 but below the consensus estimate for US$568mln
They are targeting to make a New Drug Application (NDA) for ALKS 8700 in 2018
Biogen Inc today received a thumbs up from broker heavyweight Morgan Stanley
Sales of spinal muscular atrophy drug Spinraza boosted Biogen's second quarter revenue
